바이오의약품 제조 시장 규모, 점유율, 동향 분석 보고서 : 제조 방식별, 치료법별, 질환별, 지역별 및 부문별 예측(2026-2033년)

Biologics Manufacturing Market Summary

The global biologics manufacturing market size was valued at USD 40.1 billion in 2025 and is anticipated to reach USD 140.6 billion by 2033, growing at a CAGR of 16.7% between 2026 and 2033. This growth is primarily driven by increasing demand for biopharmaceuticals, expansion of biologics production capacities, and advancements in cell and gene therapy manufacturing technologies.

Rising burden of chronic disease

One of the main factors expanding the global biologics manufacturing industry is the rising incidence of chronic illnesses such as diabetes, cancer, autoimmune diseases, and cardiovascular conditions. Biologic therapies from living organisms provide targeted and efficient treatment options for these complex conditions, as conventional treatments frequently prove insufficient. The need for novel biologic medications has increased due to the growing number of patients needing long-term, specialized care, which stimulates producers to increase their production capacity and invest in cutting-edge technologies.

Global Biologics Manufacturing Market Report Segmentation

This report forecasts revenue growth at the global, regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biologics manufacturing market report on the basis of mode, modality, disease indication, and region:

• Mode Outlook (Revenue, USD Million, 2021 - 2033)
• Contract Manufacturing
• In-house manufacturing
• Modality Outlook (Revenue, USD Million, 2021 - 2033)
• Monoclonal Antibodies (mAbs)
• Biosimilar & Recombinant Proteins
• Vaccines (recombinant/mRNA/Viral)
• Cell & Gene Therapies
• RNA-based Therapeutics
• Others
• Disease Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Autoimmune Disorders
• Infectious Diseases
• Neurological Disorders
• Cardiovascular Disorders
• Other Disease Indications
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Mode
  • 1.2.2. Modality
  • 1.2.3. Disease Indication
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Impact Analysis
    • 3.3.1.1. Rising burden of chronic disease
    • 3.3.1.2. Growing Demand for Novel and Targeted Therapies
  • 3.3.2. Market Restraint Impact Analysis
    • 3.3.2.1. High Manufacturing Costs and Capital Intensity
    • 3.3.2.2. Complex Regulatory and Quality Compliance
  • 3.3.3. Market Challenges Analysis
  • 3.3.4. Market Opportunity Analysis
• 3.4. Case Study Insights
• 3.5. Business Environment Analysis
  • 3.5.1. PESTLE Analysis
  • 3.5.2. PORTER'S Five Forces Analysis

Chapter 4. Mode Business Analysis

• 4.1. Mode Segment Dashboard
• 4.2. Global Biologics Manufacturing Market Mode, Movement Analysis
• 4.3. Global Biologics Manufacturing Market Size & Trend Analysis, by Mode, 2021 to 2033 (USD Million)
• 4.4. Contract Manufacturing
  • 4.4.1. Global contract manufacturing market estimates and forecasts, 2021 - 2033 (USD million)
• 4.5. In-house manufacturing
  • 4.5.1. Global In-house manufacturing market estimates and forecasts, 2021 - 2033 (USD million)

Chapter 5. Modality Business Analysis

• 5.1. Modality Segment Dashboard
• 5.2. Global Biologics Manufacturing Market Modality, Movement Analysis
• 5.3. Global Biologics Manufacturing Market Size & Trend Analysis, by Modality, 2021 to 2033 (USD Million)
• 5.4. Monoclonal Antibodies (mAbs)
  • 5.4.1. Global monoclonal antibodies (mAbs) market estimates and forecasts, 2021 - 2033 (USD million)
• 5.5. Biosimilar & Recombinant Proteins
  • 5.5.1. Global biosimilar & recombinant proteins market estimates and forecasts, 2021 - 2033 (USD million)
• 5.6. Vaccines (recombinant/mRNA/Viral)
  • 5.6.1. Global vaccines (recombinant/mRNA/Viral) market estimates and forecasts, 2021 - 2033 (USD million)
• 5.7. Cell & Gene Therapies
  • 5.7.1. Global cell & gene therapies market estimates and forecasts, 2021 - 2033 (USD million)
• 5.8. RNA-based Therapeutics
  • 5.8.1. Global RNA-based therapeutics market estimates and forecasts, 2021 - 2033 (USD million)
• 5.9. Others
  • 5.9.1. Global others market estimates and forecasts, 2021 - 2033 (USD million)

Chapter 6. Disease Indication Business Analysis

• 6.1. Disease Indication Segment Dashboard
• 6.2. Global Biologics Manufacturing Market Disease Indication, Movement Analysis
• 6.3. Global Biologics Manufacturing Market Size & Trend Analysis, by Disease Indication, 2021 to 2033 (USD Million)
• 6.4. Oncology
  • 6.4.1. Global Oncology market estimates and forecasts, 2021 - 2033 (USD million)
• 6.5. Autoimmune Disorders
  • 6.5.1. Global autoimmune disorders market estimates and forecasts, 2021 - 2033 (USD million)
• 6.6. Infectious Diseases
  • 6.6.1. Global infectious diseases market estimates and forecasts, 2021 - 2033 (USD million)
• 6.7. Neurological Disorders
  • 6.7.1. Global neurological disorders market estimates and forecasts, 2021 - 2033 (USD million)
• 6.8. Cardiovascular Disorders
  • 6.8.1. Global cardiovascular disorders market estimates and forecasts, 2021 - 2033 (USD million)
• 6.9. Others Disease Indications
  • 6.9.1. Global other disease indications market estimates and forecasts, 2021 - 2033 (USD million)

Chapter 7. Biologics Manufacturing Market: Regional Estimates and Trend Analysis, by Modality, Mode, & Disease Indication

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. North America biologics manufacturing market, 2021-2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Target Disease Prevalence
    • 7.3.2.3. Competitive Scenario
    • 7.3.2.4. Regulatory Framework
    • 7.3.2.5. U.S. biologics manufacturing market, 2021-2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Target Disease Prevalence
    • 7.3.3.3. Competitive Scenario
    • 7.3.3.4. Regulatory Framework
    • 7.3.3.5. Canada biologics manufacturing market, 2021-2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Target Disease Prevalence
    • 7.3.4.3. Competitive Scenario
    • 7.3.4.4. Regulatory Framework
    • 7.3.4.5. Mexico biologics manufacturing market, 2021-2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe biologics manufacturing market, 2021-2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Competitive Scenario
    • 7.4.2.4. Regulatory Framework
    • 7.4.2.5. UK biologics manufacturing market, 2021-2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. Regulatory Framework
    • 7.4.3.5. Germany biologics manufacturing market, 2021-2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Competitive Scenario
    • 7.4.4.4. Regulatory Framework
    • 7.4.4.5. France biologics manufacturing market, 2021-2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Target Disease Prevalence
    • 7.4.5.3. Competitive Scenario
    • 7.4.5.4. Regulatory Framework
    • 7.4.5.5. Italy biologics manufacturing market, 2021-2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Target Disease Prevalence
    • 7.4.6.3. Competitive Scenario
    • 7.4.6.4. Regulatory Framework
    • 7.4.6.5. Spain biologics manufacturing market, 2021-2033 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Target Disease Prevalence
    • 7.4.7.3. Competitive Scenario
    • 7.4.7.4. Regulatory Framework
    • 7.4.7.5. Denmark biologics manufacturing market, 2021-2033 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Target Disease Prevalence
    • 7.4.8.3. Competitive Scenario
    • 7.4.8.4. Regulatory Framework
    • 7.4.8.5. Sweden biologics manufacturing market, 2021-2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Target Disease Prevalence
    • 7.4.9.3. Competitive Scenario
    • 7.4.9.4. Regulatory Framework
    • 7.4.9.5. Norway biologics manufacturing market, 2021-2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific biologics manufacturing market, 2021-2033 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. Regulatory Framework
    • 7.5.2.5. Japan biologics manufacturing market, 2021-2033 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Regulatory Framework
    • 7.5.3.5. China biologics manufacturing market, 2021-2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Competitive Scenario
    • 7.5.4.4. Regulatory Framework
    • 7.5.4.5. India biologics manufacturing market, 2021-2033 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Competitive Scenario
    • 7.5.5.4. Regulatory Framework
    • 7.5.5.5. Australia biologics manufacturing market, 2021-2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Competitive Scenario
    • 7.5.6.4. Regulatory Framework
    • 7.5.6.5. Thailand biologics manufacturing market, 2021-2033 (USD Million)
  • 7.5.7. South Korea
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Competitive Scenario
    • 7.5.7.4. Regulatory Framework
    • 7.5.7.5. South Korea biologics manufacturing market, 2021-2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America biologics manufacturing market, 2021-2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. Regulatory Framework
    • 7.6.2.5. Brazil biologics manufacturing market, 2021-2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. Regulatory Framework
    • 7.6.3.5. Argentina biologics manufacturing market, 2021-2033 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA biologics manufacturing market, 2021-2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Competitive Scenario
    • 7.7.2.4. Regulatory Framework
    • 7.7.2.5. South Africa biologics manufacturing market, 2021-2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Competitive Scenario
    • 7.7.3.4. Regulatory Framework
    • 7.7.3.5. Saudi Arabia biologics manufacturing market, 2021-2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Target Disease Prevalence
    • 7.7.4.3. Competitive Scenario
    • 7.7.4.4. Regulatory Framework
    • 7.7.4.5. UAE biologics manufacturing market, 2021-2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Target Disease Prevalence
    • 7.7.5.3. Competitive Scenario
    • 7.7.5.4. Regulatory Framework
    • 7.7.5.5. Kuwait biologics manufacturing market, 2021-2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2025
• 8.4. Company Profiles/Listing
  • 8.4.1. Novartis AG
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Pfizer Inc
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Amgen Inc
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Novo Nordisk A/S
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. AbbVie Inc.
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Johnson & Johnson (Johnson & Johnson Services, Inc.)
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Bristol-Myers Squibb Company
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Eli Lilly and Company
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. F. Hoffmann La-Roche Ltd.
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Wuxi Biologics
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives
  • 8.4.11. FUJIFILM Holdings Corporation (FUJIFILM Diosynth Biotechnologies)
    • 8.4.11.1. Overview
    • 8.4.11.2. Financial Performance
    • 8.4.11.3. Product Benchmarking
    • 8.4.11.4. Strategic Initiatives
  • 8.4.12. Boehringer Ingelheim International GmbH
    • 8.4.12.1. Overview
    • 8.4.12.2. Financial Performance
    • 8.4.12.3. Product Benchmarking
    • 8.4.12.4. Strategic Initiatives
  • 8.4.13. Lonza
    • 8.4.13.1. Overview
    • 8.4.13.2. Financial Performance
    • 8.4.13.3. Product Benchmarking
    • 8.4.13.4. Strategic Initiatives
  • 8.4.14. Samsung Biologics
    • 8.4.14.1. Overview
    • 8.4.14.2. Financial Performance
    • 8.4.14.3. Product Benchmarking
    • 8.4.14.4. Strategic Initiatives